Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

Nipocalimab, an emerging therapeutic agent for hemolytic disease of the fetus and newborn (HDFN), does not appear to affect ...

The FDA approved Johnson & Johnson’s nipocalimab, which is also being studied as a potential treatment in HDFN, in myasthenia ...